Announcements Trials
Browse Landscape

Status

Completed 69Terminated 5Approved for marketing 3Unknown 2Active not recruiting 2No longer available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 1

Interventions

nilotinib 4dabrafenib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3Nivolumab 3tazemetostat 2talimogene laherparepvec 2ceritinib 2TIC10 compound 2Suspensions 2Prednisone 2Powders 2Panobinostat 2Melphalan 2Lenalidomide 2Ipilimumab 2Everolimus 2Dexamethasone 2Crizotinib 2Bortezomib 2Bevacizumab 2Axitinib 2zanubrutinib 1zanidatamab 1venetoclax 1veliparib 1tucatinib 1talquetamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Afatinib × Clear all
NCT05107193 2022-11-08

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Boehringer Ingelheim

No longer available
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡